
Kazia Therapeutics gains analyst confidence as its cancer drug shows strong preclinical results.
Kazia Therapeutics received a Buy rating from analyst firm BTIG, which raised its price target to $40, up from $34, reflecting strong confidence in the company's lead drug, paxalisib. The drug showed a 52% tumor reduction in preclinical colorectal ca...


